IPHA (Innate Pharma S.A.) Market Value to Book Value Ratio

Innate Pharma S.A. (IPHA) leverages the expertise of French immunologists who value academic freedom and prestige within the biotech sector. High trust from the global community has cemented the brand's status as an authoritative drug developer. The market dynamics reflected in the price action captured the -2.99 metric. Innate Pharma S.A. (IPHA) leads the development of NK-cell therapies, utilizing the ANKET system to create antibodies that gently activate the body's defenses against tumors.

Innate Pharma S.A (IPHA): Capitalization to Book Value Ratio from 07/04/2022 to 10/27/2026

Financial and market metric breakdowns for Innate Pharma SA (IPHA)

- price and consensus price forecast:

Stock Price Innate Pharma S.A.|IPHA - Analyst Consensus Forecast

- market capitalization data:

Market Value Innate Pharma, S.A.|IPHA - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Innate Pharma|IPHA - Accounting Capitalization|Market Capitalization to Book Value Ratio innate-pharma.com|IPHA - Cumulative Company Assets

- debt and liquidity data:

Debt to Equity Innate Pharma S.A.|IPHA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Innate Pharma, S.A.|IPHA - Company Debts|Debt to Book Capitalization Ratio Innate Pharma, S.A.

Fundamental valuation:Innate Pharma S.A.

This indicator determines the proportionality of the market value of Innate Pharma S.A. (IPHA) to its net book value, reflecting the premium or discount to real capital through the ratio of share prices to balance sheet data. Analyzing the ratio of the company's market capitalization to its book capitalization allows for an assessment of the value of its intellectual property, including the unique ANKET platform and long-term licensing agreements with global pharma behemoths.

Competitor analysis